Eisai's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Eisai manufactures and distributes pharmaceutical products.

Eisai is headquartered in Tokyo, Tōkyō Prefecture. Haruo Nai...
Read more

Annual Revenue

Employees

Haruo Naito's photo - CEO of Eisai

CEO

Haruo Naito

CEO Approval Rating

67/100

OVERVIEW

Founded:

1941

Headquarters:

TokyoTōkyō Prefecture

Status:

PublicIndependent Company of Tokyo Stock Exchange4523

Industry Sector:

- -

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Bristol Myers Squibb a competitor of Eisai?

Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Drlindamd is seen as one of Eisai's top competitors. Drlindamd was founded in null, and is headquartered in South River, New Jersey. Drlindamd operates in the industry. Drlindamd generates $6.7B less revenue vs. Eisai.

Advaxis is a top competitor of Eisai. Advaxis was founded in 2002, and its headquarters is in Princeton, New Jersey. Advaxis competes in the Biotechnology industry. Advaxis has 10,394 fewer employees than Eisai.

Inovio is Eisai's #3 rival. Inovio was founded in Plymouth Meeting, Pennsylvania} in 1979. Inovio is in the Biotechnology field. Compared to Eisai, Inovio generates $6.7B less revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Haruo Naito

CEO

- -
10,452
$0
$6.7B
1

CEO

- -
24
- -
$5.8M
2

Kenneth A. Berlin

President & CEO

87/100
90
$53.6M
$22M
3

J. Joseph Kim

President & CEO

69/100
239
$277.1M
$7.5M
4

Kenneth C. Frazier

Chairman & CEO

59/100
69,000
- -
$44.4B
5

Christophe Weber

President & CEO

58/100
27,230
$38M
$16.3B
6

Giovanni Caforio

Chairman & CEO

74/100
23,300
- -
$23.9B
7

Jean Christophe Tellier

Chairman & CEO

81/100
7,500
- -
$5.3B
8

Albert Bourla

CEO

60/100
92,400
- -
$53.7B
9

Severin Schwan

CEO

54/100
94,052
- -
$932.5M
10

David Meek

CEO

86/100
5,700
- -
$2.5B

Quarterly and Annual Revenue

Coming soon for Eisai!

Annual Revenue

$6.7B

Eisai's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 14B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Purdue Pharma LP.

May 2019

Source »
undisclosed
Purdue Pharma develops and commercializes prescription medicines for healthcare professionals and caregivers.

-

-

Sep 2006

Source »
$205M
-

These are all the companies that Eisai has acquired. Eisai has acquired 2 companies and its latest acquisition was Purdue Pharma LP. in May 2019. Purdue Pharma develops and commercializes prescription medicines for healthcare professionals and caregivers.

Investments

No recent investments found related to Eisai

Eisai News

October 1, 2019FinanzNachrichten

Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MR... See more »
October 1, 2019startupticker

Eisai teams up with Numab to generate cancer therapeutics

Under the terms of the agreement, Eisai has the option to acquire an exclusive license to develop and... See more »
October 1, 2019Biospectrum Asia

Eisai, Nichi-Iko explore generic pharma biz in China

Eisai and Nichi-Iko aim to enhance their pharmaceutical businesses in China... See more »
October 1, 2019firstwordpharma

Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (E... See more »
September 27, 2019Biospectrum Asia

Eisai, Fronteo launch Coroban prediction system for inpatients

The Coroban learns the nursing records of past inpatients at each medical institution, scores the tum... See more »
September 24, 2019FinanzNachrichten

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

TOKYO, Sept 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts wi... See more »

Eisai Press Releases

September 20, 2019PRcom

Eisai and Dream Foundation Come Together to Help Support More Veterans

Research-based human health care company to support national dream-granting organization to help more... See more »
May 29, 2019ACN Newswire

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT INCLUDING INTEGRATED ANALYSIS OF PHASE III CLINICAL STUDIES AT 33RD ANNUAL SLEEP MEETING

Tokyo, May 29, 2019 - (JCN Newswire) - Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"... See more »
May 20, 2019WebWire

"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito "Eisai") announced that Eisai has received app... See more »
May 9, 2019PR Newswire

Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII

WOODCLIFF LAKE, N.J., May 9, 2019 /PRNewswire/ -- Eisai Inc. presented the latest clinical results on... See more »
January 22, 2019PR Newswire

On-Road Driving Safety Study of Investigational Lemborexant Published in SLEEP®

TOKYO and STAMFORD, Conn., Jan. 22, 2019 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") ... See more »
January 22, 2019ACN Newswire

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time

Highest Ranked Japanese CompanyTOKYO, Jan 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been listed... See more »
January 15, 2019CENTRALCHARTS

Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium

TOKYO, Jan 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series... See more »

Headquarters

4-6-10 Koishikawa Bunkyo-ku

Tokyo, Tōkyō Prefecture112-8088

81-3-3817-3700

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Eisai manufactures and distributes pharmaceutical products. Eisai was founded in 1941. Eisai's headquarters is located in Tokyo, Tōkyō Prefecture, JP 112-8088. Eisai's latest acquisitions include Purdue Pharma LP. and . Eisai's CEO, Haruo Naito, curr...

CEO

Eisai's CEO, Haruo Naito, currently has an approval rating of 67%. Eisai's primary competitors are Drlindamd, Advaxis & Inovio.

Website

eisai.com

Frequently Asked Questions about Eisai

  1. When was Eisai founded?

    Eisai was founded in 1941
  2. Who is Eisai's CEO?

    Eisai's CEO is Haruo Naito
  3. How much revenue does Eisai generate?

    Eisai generates $6.7B in revenue
  4. How much funding does Eisai have?

    Eisai has historically raised $0 in funding
  1. Where is Eisai's headquarters?

    Eisai's headquarters is in Tokyo Tōkyō Prefecture, JP
  2. How many employees does Eisai have?

    Eisai has 10,452 employees
  3. Who are Eisai's competitors?

    Eisai's top competitors are Drlindamd, Advaxis, Inovio